Skip to content
Educational information only. Not medical advice. We sell nothing and take no affiliate money.
By /
PeptideMostly animalNot FDA approved

Chonluten

Glu-Asp-Gly tripeptide

Last reviewed October 27, 2026 · 8 sources · Written for general readers · Compare with another compound →

The bottom line

Chonluten is a three amino acid peptide from the Khavinson group, sold online for the lungs and stomach. Its research is a few cell studies and one rat stomach ulcer study, all tied to that group.[1][2] We found no published human studies and no tests in lung disease.

Where the evidence stands

What it is

Chonluten is the trade name for EDG, a chain of three amino acids: glutamic acid, aspartic acid and glycine. A 2022 paper describes it as a lab made copy of a peptide from lung and airway tissue.[1] It comes from the short peptide program of Vladimir Khavinson in St. Petersburg.

Its stomach claim rests on a rat ulcer study of a peptide coded T-34, which PubMed indexes as glutamyl aspartyl glycine.[2] A rat skin study by a related team also lists T-34 as Glu-Asp-Gly.[3]

Name
Chonluten (Glu-Asp-Gly tripeptide)
Other names
EDG, T-34, glutamyl aspartyl glycine
Type
Peptide
Sequence
EDG

What it does in the body

Chonluten is a lab made chain of three amino acids, glutamic acid, aspartic acid and glycine, described as a copy of a peptide from lung and airway tissue.[1] It is not a known hormone and has no known receptor. Its developers say it changes how genes for inflammation and cell protection are switched on, but this rests on a few lab and rat studies.[2]

This is the biology, area by area. A change measured in the body, like a higher blood level, does not always mean a person feels a benefit. The claims check below covers that.

Gut

Seen in animals

In rats with stomach ulcers caused by a chemical, a peptide coded T-34, indexed as EDG, was reported to bring protective antioxidant and anti inflammation proteins back toward normal by acting on their genes. The summary gives no numbers or group sizes.[2]

Immune system

Lab finding

In a human immune cell line grown in a dish, Chonluten activated a signal called STAT1, sped up cell growth and cut the release of the inflammation signals TNF and IL6 after a bacterial toxin.[1] On its own, though, it caused a slight TNF release and was the only one of five peptides that raised cell death, at about double the rate of the others.[1]

Skin and hair

Lab finding

In skin tissue taken from young rats and kept alive in a dish, four of five related tripeptides boosted cell growth, but T-34, which is EDG, did not, and in skin from old rats only a different tripeptide had a clear effect.[3]

Absorption and transport

Lab finding

A computer modeling study by the group predicted EDG is among the short peptides best carried into cells by gut and cell membrane transport proteins. This was a prediction, not a measurement in animals or people.[4]

How it works

The group says Chonluten changes how genes for inflammation and cell protection are switched on.

  • In a human immune cell line grown in a dish, it activated a signal called STAT1 and changed growth signals.[1]
  • A computer modeling study by the group predicted EDG is among the peptides best carried into cells by gut and cell membrane transport proteins, and suggested this might explain antitumor effects claimed for it.[4]
  • In rats with stomach ulcers, T-34 was reported to bring protective antioxidant and anti inflammation proteins back toward normal by acting on their genes.[2]

This is a lab and computer based theory from the developer's group and has not been shown in people.

What the research shows

We keep animal and human evidence apart. A result in animals is a reason to study something in people, not proof that it works in people.

Animal and lab studies

One rat ulcer study and a few lab studies

  • In rats with chemically caused stomach ulcers, T-34 normalized protective proteins, but the summary gives no numbers or group sizes.[2]
  • In skin tissue from young rats, T-34 was the only one of five tripeptides tested that did not boost cell growth.[3]
  • In a human immune cell line, Chonluten and four other Khavinson peptides all sped up cell growth and cut release of the inflammation signals TNF and IL6 from activated cells.[1]
  • In that study, Chonluten was the only peptide that raised cell death, at roughly double the rate of the others, and on its own it caused a slight release of TNF.[1]
  • That cell study was run by an Italian university team, with Khavinson as a coauthor.[1]

Limit: These are small lab and rat studies with no independent replication and no tests of lung disease in living animals.

Human studies

No human studies

  • We found no published clinical trials of Chonluten or EDG in people. The only human material studied was a line of immune cells grown in a dish.[1]

Limit: Without human trials, there is no evidence it helps lungs or the stomach in people or that it is safe to use.

Claims check

The most common claims about this compound, and what studies actually found. Verdicts rate the evidence, not whether you should use it.

Supports lung and airway health

Not tested

No study has tested Chonluten in lung disease in animals or people. The closest work is one study of immune cells in a dish, where it lowered some inflammation signals but also raised cell death.[1]

Heals stomach ulcers and supports the gut

Only in animals

In rats with chemically caused stomach ulcers, a peptide coded T-34, indexed as EDG, normalized protective proteins. The summary gives no numbers.[2] It has not been tested in people with ulcers.

Lowers inflammation

Only in animals

In a human immune cell line, it cut release of TNF and IL6 from activated cells, but on its own it caused a slight TNF release and more cell death than the other peptides tested.[1] No animal or human study has measured inflammation in the whole body.

Slows aging

Not tested

The group calls T-34 a geroprotective peptide, meaning one meant to protect against aging, but the only living animal study we found looked at stomach ulcers in rats.[2] No study has measured aging in animals or people.

Renews skin and tissue

Not tested

In young rat skin tissue kept alive in a dish, EDG was the one tripeptide of five that did not boost cell growth.[3] No study has tested skin or tissue renewal with it in living animals or people, so nothing supports this claim.

Known risks and side effects

  • Unregulated products. It is sold online outside pharmacies with no FDA review, so what is in the vial or capsule, how pure it is, and how much it holds are unknown.[5]
  • No human safety data. No human trials have been published, so side effects are unknown. In the cell study it raised cell death in a line of immune cells.[1]
  • One research group. Nearly all the research comes from the developer's network, and outside teams have not repeated it.[2][4]
  • Banned in sport. WADA bans unapproved drugs at all times, in and out of competition, and keeps that rule in its 2027 list.[6][7]

Regulatory status

Today: It is not approved by the FDA for any use. It is not named on FDA's list of risky bulk substances for compounding as updated April 22, 2026, or on FDA's list of substances nominated for pharmacy compounding as updated May 14, 2026.[5][8] WADA does not name Chonluten, but its 2026 list and its 2027 list, in force January 1, 2027, ban at all times any drug not approved by a government health agency for human use, so athletes should treat it as banned unless their anti doping agency says otherwise.[6][7]

Sources

  1. Avolio F, Martinotti S, Khavinson VK, Esposito JE, Giambuzzi G, Marino A, Mironova E, Pulcini R, Robuffo I, Bologna G, Simeone P, Lanuti P, Guarnieri S, Trofimova S, Procopio AD, Toniato E. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022;23(7):3607. PMID 35408963
  2. Khavinson VKh, Lin'kova NS, Dudkov AV, Polyakova VO, Kvetnoi IM. Peptidergic regulation of expression of genes encoding antioxidant and anti-inflammatory proteins. Bull Exp Biol Med. 2012;152(5):615-8. PMID 22803148
  3. Voicekhovskaya MA, Chalisova NI, Kontsevaya EA, Ryzhak GA. Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats. Bull Exp Biol Med. 2012;152(3):357-9. PMID 22803085
  4. Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules. 2023;13(3):552. PMID 36979488
  5. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. FDA
  6. World Anti-Doping Agency. The 2026 Prohibited List, World Anti-Doping Code International Standard. In force January 1, 2026. WADA 2026
  7. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force January 1, 2027. WADA 2027
  8. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026. FDA 503A list
Medical disclaimer

This page is educational information only. It is not medical advice and does not replace care from a licensed medical provider. Do not use this page to decide whether to take any substance. Talk to a licensed medical provider first.

Found an error or a newer study? We correct pages fast.

Report a correction →
Scroll to Top